The French journal of urology最新文献

{"title":"Complications and causes of readmission following retropubic versus transobturator midurethral sling surgery in 88,880 patients.","authors":"Alicia Blondeau, Alice Pitout, Clément Larose, Debora Koffi, Jean Luc Gaudry, Pascale Eschwege, Antoine Paris, Charles Mazeaud","doi":"10.1016/j.fjurol.2026.103096","DOIUrl":"10.1016/j.fjurol.2026.103096","url":null,"abstract":"<p><strong>Introduction: </strong>Stress urinary incontinence (SUI) is a major public health concern. The success rate of synthetic mid-urethral sling (MUS) procedures generally remains high. However, safety concerns persist. This study aimed to evaluate MUS removal rates removal rates between transobturator (TOT) and retropubic (TVT), with secondary outcomes focusing on complication incidence and the occurrence of new MUS placement after TVT and transobturator TOT procedures.</p><p><strong>Material: </strong>Data were extracted from the French national hospital database for all hospitalizations related to MUS procedures performed between 2016 and 2024. Only patients treated with MUS from 2016 to 2019 were included to ensure a 5-year follow-up. Complications were recorded during the initial hospitalization and any subsequent rehospitalizations within 60 months postoperatively. MUS associated with pelvic organ prolapse mesh placement were excluded using the CCAM codes.</p><p><strong>Results: </strong>Between 2016 and 2019, 69,879 TOT and 19,001 TVT procedures were included. The TVT group exhibited higher rates of sling removal (HR 0.50, CI95%=[0.47-9.53], P<0.001) and urinary tract infections (0.7 vs. 0.5%, P<0.01). In contrast, the TOT group had a 19% higher reintervention rate for SUI (HR=1.19, CI95%=[1.10-1.29], P<0.001).</p><p><strong>Conclusion: </strong>Although TVT is associated with a slightly higher rate of perioperative complications, it has become more efficient over time compared to TOT. However, the available evidence does not support preferential use of TOT given its higher risk of repeat surgery for SUI. Further large-scale studies are needed to more accurately assess comparative complication profiles.</p><p><strong>Level of evidence: 4: </strong></p>","PeriodicalId":516865,"journal":{"name":"The French journal of urology","volume":" ","pages":"103096"},"PeriodicalIF":1.2,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147461325","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Management of bladder pain syndrome with Hunner's lesions: A series of 32 cases.","authors":"Christian Saussine, Victor Gaillard","doi":"10.1016/j.fjurol.2026.103149","DOIUrl":"10.1016/j.fjurol.2026.103149","url":null,"abstract":"<p><strong>Introduction: </strong>The recommendations of the European association of urology (EAU) suggests treating the bladder phenotype with Hunner's lesion (HL) associated with bladder pain syndrome (BPS) by transurethral resection (TUR) or coagulation of the lesions. We present the results of this approach in our practice.</p><p><strong>Materials: </strong>Retrospective monocentric study including consecutive patients presenting BPS with HL assessed during cystoscopy between 1998 and 2026. Patients were divided in two groups according to treatment strategy: group 1 with medical management (association of cimetidine or bladder instillations of RIMSO or pentosan polysulfate de sodium [CRP]) and group 2 with surgical management (immediate TUR, repeated if pain and HL recurrence). The primary objective was to compare success of each management strategy, defined by complete resolution of pain. Secondary objectives were to describe efficacy on pollakiuria symptoms and morbidity of surgical management.</p><p><strong>Results: </strong>Thirty-two patients were included (group 1 n=9, group 2 n=23). Success of treatment was achieved in 11.1% (1/9) cases in group 1 and in 78.2% (18/23) cases in group 2 (P=0.001). In group 1, the only pain resolution was observed after RIMSO bladder instillation. In group 2, 61.1% (11/18) experienced a pain recurrence after being cured with a median delay of 13 [6-30.25] months. Twelve patients required a 2nd TUR. Resolution of pollakiuria occurred in 0% in group 1 and 34.8% (8/23) in group 2 (P=0.07). Three patients required reintervention after TUR, 2 for bladder perforation (1 open and 1 laparoscopic bladder repair), 1 for gross haematuria requiring coagulation and 12.5% (4/32) patients ultimately underwent cystectomy.</p><p><strong>Conclusion: </strong>In case of BPS with a bladder phenotype and one or more Hunner's lesions, treatment by transurethral resection of the inflammatory lesion is more effective for pain and, to a lesser extent, for pollakiuria than our usual medical treatment (CRP) but does not prevent recurrence after varying periods of time.</p><p><strong>Level of evidence: 5: </strong></p>","PeriodicalId":516865,"journal":{"name":"The French journal of urology","volume":" ","pages":"103149"},"PeriodicalIF":1.2,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148274477","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Extraperitoneal versus transperitoneal robot-assisted laparoscopic total prostatectomy: Comparison after propensity score matching.","authors":"Maximin Pourchet, Guillaume Guichard, François Kleinclauss, Alexandre Frontczak","doi":"10.1016/j.fjurol.2026.103159","DOIUrl":"10.1016/j.fjurol.2026.103159","url":null,"abstract":"<p><strong>Background: </strong>Robot-assisted laparoscopic radical prostatectomy (RALRP) has become the standard surgical approach for the treatment for localized prostate cancer. Two main surgical site access are commonly used: transperitoneal (TP) and extraperitoneal (EP). While high-volume specialized centers have demonstrated comparable outcomes between these two techniques, data from real-world clinical practices remain limited. The aim of our study was to compare the morbidity and oncological outcomes of RALRP via TP and EP in a standard clinical setting, outside of high-specialty centers.</p><p><strong>Method: </strong>We conducted a retrospective monocentric cohort study including 210 patients who underwent surgery between 2016 and 2024. After propensity score matching, 52 patients who underwent surgery via the TP approach were compared to 52 patients who underwent surgery via the EP approach, with a single surgeon performing each technique. The outcomes assessed included complications according to the Clavien-Dindo classification, surgical margins, and biochemical recurrence.</p><p><strong>Results: </strong>The two groups were comparable in terms of preoperative characteristics. The overall complication rate was not significantly different (27% vs 29%, P=0.83). The rates of positive surgical margins (33% TP vs 23% EP, P=0.64) and biochemical recurrence (17% vs 12%, P=0.40) were also comparable.</p><p><strong>Conclusion: </strong>After propensity score matching, the EP and TP approaches were associated with comparable perioperative morbidity and oncological outcomes in an intermediate-volume centre. Although no statistically significant difference was detected between the two techniques, the limited statistical power of our study does not allow these findings to be considered as formal evidence of oncological equivalence.</p><p><strong>Level of evidence: </strong>Grade C.</p>","PeriodicalId":516865,"journal":{"name":"The French journal of urology","volume":" ","pages":"103159"},"PeriodicalIF":1.2,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148414640","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"p16 status and histopathological prognostic factors in penile squamous cell carcinoma.","authors":"Anaïs Chhang, Clément Dumont, Florian Herms, Bénédicte Cavelier-Balloy, Pierre Mongiat-Artus, François Desgrandchamps, Annabelle Goujon","doi":"10.1016/j.fjurol.2026.103228","DOIUrl":"10.1016/j.fjurol.2026.103228","url":null,"abstract":"<p><strong>Background: </strong>Penile squamous cell carcinoma (PSCC) is a rare malignancy that may develop following persistent infection with human papillomavirus (HPV). The prognostic value of HPV status remains controversial.</p><p><strong>Objective: </strong>To evaluate the impact of p16 status, a surrogate marker of high-risk HPV-driven carcinogenesis, and selected histopathological features on survival outcomes in PSCC, and to assess their interrelationships.</p><p><strong>Design, setting and participants: </strong>This retrospective single-center study included 87 patients treated for PSCC at Saint-Louis Hospital (Paris, France) between 2015 and 2024.</p><p><strong>Outcome measurements and statistical analyses: </strong>Associations between p16 status and histopathological features (pT stage, pN stage, tumor grade, lymphovascular invasion, and perineural invasion) were assessed using Chi-squared tests. Their impact on disease-specific survival (DSS) and overall survival (OS) was analyzed using Kaplan-Meier curves and log-rank tests.</p><p><strong>Results: </strong>Thirty-seven patients (43%) had p16-positive tumors. p16 status was not associated with tumor stage, nodal status, lymphovascular invasion, or perineural invasion. p16-positive tumors were significantly associated with higher histological grade (P<0.001). Factors associated with poorer 3-year DSS included nodal involvement (54.4 vs. 100%, P<0.001), lymphovascular invasion (52.5 vs. 90.9%, P=0.024), and perineural invasion (59.9 vs. 91.4%, p<0.01). p16 status was not associated with DSS (P=0.68).</p><p><strong>Conclusions: </strong>In this retrospective single-center cohort, p16 status was not significantly associated with DSS in univariate analysis. Nodal involvement, lymphovascular invasion, and perineural invasion were the variables most strongly associated with prognosis in the univariate analyses.</p><p><strong>Level of evidence: 3: </strong></p>","PeriodicalId":516865,"journal":{"name":"The French journal of urology","volume":" ","pages":"103228"},"PeriodicalIF":1.2,"publicationDate":"2026-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149083559","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic performance of 29-MHz micro-ultrasound using cognitive fusion with multiparametric MRI for the detection of clinically significant prostate cancer: a single-center retrospective study.","authors":"Cedric Idri, Floriane Michel, Michel Soulie, Matthieu Thoulouzan, Nicolas Doumerc, Mathieu Roumiguie, Thibaut Brierre, Xavier Game, Anne-Sophie Bajeot","doi":"10.1016/j.fjurol.2026.103230","DOIUrl":"https://doi.org/10.1016/j.fjurol.2026.103230","url":null,"abstract":"<p><strong>Introduction: </strong>The aim of this study was to evaluate the diagnostic performance of 29-MHZ micro-ultrasound with cognitive fusion based on multiparametric MRI for the detection of clinically significant prostate cancer.</p><p><strong>Materials and methods: </strong>A single-center retrospective study included 185 patients who underwent targeted prostate biopsies between January 2022 and December 2023. Biopsies were all performed with a 29-MHz high-resolution micro-ultrasound system, combined with cognitive fusion based on prior prostate MRI. Primary endpoint was the detection rate of clinically significant prostate cancer defined as ISUP grade ≥ 2. MRI-ultrasound discordances were also analysed, as well as the diagnostic performance of the PRI-MUS score.</p><p><strong>Results: </strong>The overall prostate cancer detection rate was 68%, with a clinically significant cancer detection rate of 47%. MRI-ultrasound concordance was observed in 152 patients, with a 50% detection rate for ISUP grade ≥ 2 cancers. Among ultrasound targets not identified on MRI, three clinically significant cancers were detected. The PRI-MUS score showed a sensitivity of 75%, a specificity of 36%, and an AUC of 0.66.</p><p><strong>Conclusion: </strong>29-MHz micro-ultrasound combined with cognitive fusion based on multiparametric MRI demonstrated good diagnostic performance for the detection of clinically significant prostate cancer. Micro-ultrasound may represent a complementary imaging modality to MRI, particularly in cases of MRI-ultrasound discordance.</p>","PeriodicalId":516865,"journal":{"name":"The French journal of urology","volume":" ","pages":"103230"},"PeriodicalIF":1.2,"publicationDate":"2026-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149077326","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sequential intravesical gemcitabine-docetaxel after BCG failure non-muscle invasive bladder cancer: Oncological outcomes and safety profile.","authors":"Albane Massiet du Biest, Evanguelos Xylinas, Pierre-Etienne Gabriel","doi":"10.1016/j.fjurol.2026.103229","DOIUrl":"10.1016/j.fjurol.2026.103229","url":null,"abstract":"<p><strong>Introduction: </strong>Sequential intravesical instillation of gemcitabine and docetaxel (Gem/Doce) has emerging evidence as a bladder-sparing approach in BCG failure non-muscle-invasive bladder cancer (NMIBC). This study aimed to provide additional real-world data by reporting the oncological outcomes and safety profile of Gem/Doce in BCG-failure NMIBC.</p><p><strong>Methods: </strong>We conducted a retrospective single-arm monocentric study including all consecutive patients treated with Gem/Doce for BCG-failure NMIBC between 2023 and 2025. Oncological outcomes included overall recurrence-free survival (RFS), high-grade (HG) RFS, progression-free survival (PFS), cystectomy-free survival (CFS), metastasis-free survival (MFS), and overall survival (OS). Adverse events (AEs) were graded using CTCAE criteria.</p><p><strong>Results: </strong>A total of 47 patients were included. Median number of instillations was 10 (IQR 6-14). After a median follow-up of 12.6 months (11.6-19.7), 10 (21.3%) patients experienced disease recurrence or progression, including 5 (10.6%) with HG recurrence and 1 (2.1%) with muscle-invasive disease. Three (6.4%) patients underwent radical cystectomy, three (6.4%) developed metastases, and three (6.4%) died, including one (2.1%) from bladder cancer. 1-year RFS and HG-RFS were 89.3% (80-99.8) and 94.3% (87-100). 1-year PFS, CFS, MFS, and OS were 96.8%, 95.4%, 97.9%, and 95.3%. In BCG-unresponsive NMIBC, 1-year RFS, HG-RFS and MFS were 91.4%, 95.5% and 96.4%. Among patients with systematic bladder biopsies (n=15 at 3 months and n=9 at 12 months), 4 (26.7%) were positive at 3 months and 3 (33.3%) at 12 months. AEs occurred in 70.2% (grade 1-2) and 6.4% (grade ≥3), mainly urinary frequency, urgency, and asthenia.</p><p><strong>Conclusion: </strong>Gem/Doce shows promising real-world oncological efficacy with an acceptable safety profile in BCG-failure NMIBC, although optimal surveillance strategies remain to be defined.</p><p><strong>Level of evidence: 4: </strong></p>","PeriodicalId":516865,"journal":{"name":"The French journal of urology","volume":" ","pages":"103229"},"PeriodicalIF":1.2,"publicationDate":"2026-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149077392","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Basic urological procedure workshops during pre-surgical residency bootcamp: Outcomes from a French university hospital.","authors":"Thomas Prudhomme, Anne Sophie Bajeot, Marie Laure Lier, Charlotte Martin, Vincent Minville, Fabrice Muscari, Nicolas Carrère, Cyril Podio, Charles-Henri Houze-Cerfon, Thomas Geeraerts, Xavier Gamé, Olivier Abbo, Etienne Buscail","doi":"10.1016/j.fjurol.2026.103201","DOIUrl":"10.1016/j.fjurol.2026.103201","url":null,"abstract":"<p><strong>Introduction: </strong>The transition from graduate medical school to residency is often considered as the most difficult transition by residents and supervisors. At our institution, a bootcamp for future surgical residents was set up in 2020. The aim of this study is to present the outcomes of the basic urological procedure workshops during this bootcamp. We specifically evaluated the contribution of video support to learning urethral and suprapubic catheter insertion through a comparative study.</p><p><strong>Methods: </strong>We were able to study two consecutive years of students (October 2023 and 2024). Starting in 2023, some basic urological procedure workshops were set up during the bootcamp: a urethral catheter insertion workshop, a suprapubic catheter placement workshop and a cystoscopy workshop. The urethral catheter insertion and suprapubic catheter placement workshops were comparative between two groups of students: a group with video support (Video group) one week before the bootcamp and another group without video support (Control group). Two members of the surgical teaching team performed the evaluation under blind conditions. At the end of the bootcamp, feedback was collected from the students. Therefore, a questionnaire and a Likert scale were sent to each student at the beginning of January, two months after the start of the course.</p><p><strong>Results: </strong>The cohort included 62 students, 32 from the 2023 class and 30 from the 2024 class. Concerning the urethral catheter insertion, the OSATS overall score was significantly better for the students in the 'video' group (medians 38.0 [36.0-40.0] vs. 34.0 [29.0-40.0], P=0.02). Concerning the suprapubic catheter placement, the OSATS overall score was not significantly different between the 'video' and the control group (medians 25.0 [19.5-37.0] vs. 28.0 [22.0-38.0], P=0.6). However, this comparison was underpowered (n=11) and should not be interpreted as demonstrating equivalence. The outcomes of the questionnaire showed the importance of this workshop for the students.</p><p><strong>Conclusion: </strong>The implementation of basic urological procedure practice during our pre-residency bootcamp may help prepare future residents to perform urinary drainage. This bootcamp will be continued by consolidating the general foundations common to all future residents, regardless of their specialty.</p><p><strong>Level of evidence: </strong>Level 4.</p>","PeriodicalId":516865,"journal":{"name":"The French journal of urology","volume":" ","pages":"103201"},"PeriodicalIF":1.2,"publicationDate":"2026-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148922455","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk stratification in non-muscle-invasive bladder cancer in the era of expanding therapeutic options: Are current classifications still adequate?","authors":"Igor Duquesne, Mohamad Abou Chakra, Alexandre de la Taille, Michael A O'Donnell, Géraldine Pignot","doi":"10.1016/j.fjurol.2026.103200","DOIUrl":"10.1016/j.fjurol.2026.103200","url":null,"abstract":"<p><strong>Background: </strong>NMIBC risk classifications from AFU, EAU, AUA/SUO and NCCN were derived decades ago to estimate recurrence and progression, but the therapeutic landscape has since expanded, gene therapy, an IL-15 superagonist, systemic immunotherapy, and BCG-combination regimens, raising the question of whether these classifications remain adequate to guide treatment selection.</p><p><strong>Objective: </strong>To determine whether contemporary NMIBC risk classifications remain adequate for treatment selection, or function as prognostic instruments applied beyond their original purpose.</p><p><strong>Data sources: </strong>PubMed/MEDLINE, AFU/EAU/AUA-SUO/NCCN guideline portals, FDA/EMA databases, and ClinicalTrials.gov, searched from January 2000 to August 2026.</p><p><strong>Study selection: </strong>Narrative review prioritizing original derivation and validation studies of risk models, pivotal randomized trials, and current guideline texts over secondary or conference-only sources, flagged as such throughout.</p><p><strong>Results: </strong>AFU, EAU, AUA/SUO and NCCN diverge architecturally, producing discordant classifications for identical patients, most sharply for low-burden Ta high-grade disease and T1 disease with concomitant CIS. Four agents now hold FDA approval for BCG-unresponsive disease, and two of three recent phase III trials in BCG-naive high-risk disease (CREST, POTOMAC) were positive, but eligibility depends on treatment-exposure definitions outside baseline risk labels; real-world adherence to adequate BCG is below 50%. MRI/VI-RADS shows strong accuracy for muscle invasion but remains unvalidated for risk stratification. We propose a seven-axis, treatment-oriented framework, reassessed at clinical checkpoints, illustrated with two worked examples.</p><p><strong>Limitations: </strong>Narrative, not systematic, review; some evidence is conference-sourced pending peer-reviewed publication, and the framework is not yet validated.</p><p><strong>Conclusion: </strong>Current classifications remain necessary but insufficient alone; treatment selection increasingly requires a dynamic, multi-axial framework reassessed at defined checkpoints rather than fixed at diagnosis.</p>","PeriodicalId":516865,"journal":{"name":"The French journal of urology","volume":" ","pages":"103200"},"PeriodicalIF":1.2,"publicationDate":"2026-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148922439","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"For couples in assisted reproduction programmes, concurrent male and female infection with human papillomavirus might be associated with a longer time to clinical pregnancy and a lower live birth rate.","authors":"Jefferson Gardet, Armin Priam, Moncef Benkhalifa, Baptiste Demey, Rosalie Cabry, Dorian Bosquet, Fabien Saint","doi":"10.1016/j.fjurol.2026.103199","DOIUrl":"10.1016/j.fjurol.2026.103199","url":null,"abstract":"<p><strong>Introduction: </strong>We assessed in a prospective previous study the association between the human papillomavirus (HPV) status of infertile men and the presence of sperm abnormalities (oligospermia, asthenospermia, and/or teratospermia). However, few studies have reported on the impact of HPV infection on pregnancy rates and live birth rates.</p><p><strong>Materials and methods: </strong>From May to October 2021, we prospectively collected clinical, laboratory, and infection-related data (including HPV status) from 461 men consulting for infertility. We subsequently collected the same data on the men's partners, to assess the impact of both male HPV infections and concurrent couple HPV infections on treatment outcomes. Pregnancy outcomes were assessed using the Kaplan-Meier method.</p><p><strong>Results: </strong>Seventy-eight couples were screened for HPV infection. The rate of spontaneous and medically assisted pregnancies was higher among couples with an HPV- male than among couples with an HPV+ male (58.7% vs. 37.5%; P=NS), as was the live birth rate (50% vs. 28%; P=NS). The spontaneous and medically assisted pregnancy rate was higher in HPV- couples than in HPV+ couples (60.5% vs. 37.1%; P=0.06), as was the live birth rate (51% vs. 28%; P=NS). However, time to clinical pregnancy was not significantly longer in HPV+ couples than HPV- couples (P=0.05).</p><p><strong>Conclusion: </strong>Couples being assessed for infertility should be systematically screened for HPV. Concurrent HPV positivity appears to be associated with a lower likelihood of pregnancy and a lower birth rate.</p><p><strong>Level of evidence: </strong>Level 2b.</p>","PeriodicalId":516865,"journal":{"name":"The French journal of urology","volume":" ","pages":"103199"},"PeriodicalIF":1.2,"publicationDate":"2026-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148908404","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Discovery of potential new drug targets for cystitis and chronic cystitis: A drug target Mendelian randomization study.","authors":"Zilong Liang, Conglei Hu, Zeyu Wang, Rui Ma, Yancai Ding, Yongxiang Shao","doi":"10.1016/j.fjurol.2026.103196","DOIUrl":"10.1016/j.fjurol.2026.103196","url":null,"abstract":"<p><strong>Background: </strong>Acute cystitis is a common bacterial infection, and its progression to chronic forms poses significant challenges due to limitations of antibiotic therapy. We aimed to identify novel drug targets for cystitis using a Mendelian randomization approach.</p><p><strong>Methods: </strong>We integrated plasma protein data (from DECODE and UKB-PPP) and eQTL data (from eqtlGEN) as exposures, with cystitis (FinnGEN) and chronic cystitis (LeeLab) data as outcomes. Analyses included MR, SMR, Bayesian colocalization, and HEIDI tests. Promising targets underwent druggability assessment, PheWAS, and PPI analysis.</p><p><strong>Results: </strong>We identified eight potential targets for cystitis and one specific to chronic cystitis. Positive regulators included BTN3A2, H2BC5, HLA-DQA1, HLA-DQB1, and MARK3; negative regulators were TNXB, BTN2A1, and HLA-DQB2. MYCBPAP was a negative regulator specific to chronic cystitis. After validation, MARK3 and HLA-DQA1 were classified as Tier 2 (druggable), MYCBPAP as Tier 1, and others as Tier 3. PheWAS and PPI analyses indicated no major side effects or interactions for MARK3 and HLA-DQA1.</p><p><strong>Conclusion: </strong>MARK3 and HLA-DQA1 are promising drug targets for cystitis. Inhibition of these proteins may offer therapeutic benefits. Further experimental validation is required. MYCBPAP represents a specific potential target for chronic cystitis, warranting future investigation.</p><p><strong>Level of evidence: </strong>Level II, Mendelian randomization study.</p>","PeriodicalId":516865,"journal":{"name":"The French journal of urology","volume":" ","pages":"103196"},"PeriodicalIF":1.2,"publicationDate":"2026-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148898796","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}